Tag:

ImmunoCellular Therapeutics

Latest Headlines

Latest Headlines

Hastings, McGirr to sit on Relypsa board

FierceBiotech | January 4, 2013
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...

ImmunoCellular taps Andrew Gengos to serve as president

FierceBiotech | December 6, 2012
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...

UPDATED: Drug developers extol human data in brain cancer fight

FierceBiotech | June 6, 2012
A trio of programs in development was highlighted in a Bloomberg article that sheds light on the tricky--and often losing--battle against deadly brain cancer called glioblastoma multiforme.

ImmunoCellular licenses new ovarian cancer target

March 22, 2012
ImmunoCellular Therapeutics' vaccine, ICT-140, is a cell-based vaccine in early development for the treatment of ovarian cancer.

ImmunoCellular starts Phase II trial of brain cancer vaccine

January 10, 2012
Wake Forest Baptist Medical Center is heralding its involvement in a new Phase II trial of ImmunoCellular Therapeutics ' ICT-107. The cancer vaccine, which we recently chose as one of 10 promising

ImmunoCellular gains brain cancer vax patent

June 22, 2011
Los Angeles-based biotech ImmunoCellular Therapeutics has received a patent for its glioblastoma vaccine, ICT-107. The patent, named "System and method for the treatment of cancer, including cancers

Brain cancer vax promising in PhI

June 3, 2010
A small Phase I trial of an experimental dendritic cell-based brain cancer vaccine advanced by ImmunoCellular Therapeutics (IMUC) has produced some unusually positive results. Only 16 patients

Brain cancer vax looks promising in small trial

FierceBiotech | June 2, 2010
A small Phase I trial of an experimental dendritic cell based brain cancer vaccine advanced by ImmunoCellular Therapeutics (IMUC) has produced some unusually positive results. Only 16 patients
Related Tags

ImmunoCellular Therapeutics Press Releases

  • ImmunoCellular Therapeutics Licenses Novel Immunotherapeutic Target EphA2 from University of Pittsburgh
  • ImmunoCellular Therapeutics Licenses Mesothelin Cancer Antigen from Johns Hopkins University
  • ImmunoCellular Therapeutics Receives Notice of Allowance of Cancer Stem Cell Targeting Patent
  • ImmunoCellular Therapeutics, Ltd Signs Agreement with Formatech, Inc. for Development of Optimal Cancer Stem Cell Vaccine
Press Releases
  • Nagasaki University and Astellas Launch Collaborative Research for Screening New Anti-Dengue Virus Drugs for Neglected Tropical Diseases
  • Tokyo Institute of Technology and Astellas Launch Collaborative Research for New Anti-Dengue Virus Drugs for Neglected Tropical Diseases
  • Scripps Research Institute Study Underlines Potential of New Technology to Diagnose Disease
  • Study Finds New Genetic Test Better Predicts Mother's Risk of Having a Child With Fragile X Syndrome
  • Effect of Genzyme's LEMTRADA™ Maintained in Patients Beyond Two-Year Pivotal MS Studies
  • More Press Releases
Featured Jobs
  • Validation Engineer - St. Louis, MO area
    ProPharma Group -
  • Chief Scientific Officer
    The Leukemia & Lymphoma Society - White Plains, NY
  • Engineering/Facilities Technician
    CMC Biologics - San Francisco, CA
  • Clinical Nurse Consultant - Tampa Job
    Celgene Corporation - Tampa, FL, US
  • Senior Director, National & Regional Accounts Job
    Celgene Corporation - Summit, NJ, US
Sponsored Links